{"id":"https://openalex.org/W4229597174","doi":"https://doi.org/10.1016/j.bmcl.2020.127433","title":"Optimization of a series of potent, selective and orally bioavailable SYK inhibitors","display_name":"Optimization of a series of potent, selective and orally bioavailable SYK inhibitors","publication_year":2020,"publication_date":"2020-07-24","ids":{"openalex":"https://openalex.org/W4229597174","doi":"https://doi.org/10.1016/j.bmcl.2020.127433"},"language":"en","primary_location":{"id":"doi:10.1016/j.bmcl.2020.127433","doi":"https://doi.org/10.1016/j.bmcl.2020.127433","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bmcl.2020.127433","pdf_url":null,"source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry Letters","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5048914331","display_name":"Neil P. Grimster","orcid":"https://orcid.org/0000-0003-0088-1250","observed_orcids":["https://orcid.org/0000-0003-0088-1250"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Neil P. Grimster","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA. Electronic address: neil.grimster@astrazeneca.com","Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":"https://orcid.org/0000-0003-0088-1250","affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA. Electronic address: neil.grimster@astrazeneca.com","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022583730","display_name":"Lakshmaiah Gingipalli","orcid":"https://orcid.org/0000-0001-6465-0705","observed_orcids":["https://orcid.org/0000-0001-6465-0705"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lakshmaiah Gingipalli","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068952265","display_name":"Bernard C. Barlaam","orcid":"https://orcid.org/0000-0002-0904-7556","observed_orcids":["https://orcid.org/0000-0002-0904-7556"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Bernard Barlaam","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001064231","display_name":"Qibin Su","orcid":"https://orcid.org/0000-0003-3394-3614","observed_orcids":["https://orcid.org/0000-0003-3394-3614"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qibin Su","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109203504","display_name":"Xiaolan Zheng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"XiaoLan Zheng","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110621795","display_name":"David W. Watson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David Watson","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Haixia Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haixia Wang","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053281079","display_name":"Iain D. Simpson","orcid":"https://orcid.org/0009-0005-0675-5206","observed_orcids":["https://orcid.org/0009-0005-0675-5206"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Iain Simpson","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005150760","display_name":"Andy Pike","orcid":"https://orcid.org/0000-0001-6078-7501","observed_orcids":["https://orcid.org/0000-0001-6078-7501"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Andy Pike","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037190863","display_name":"Amber Balazs","orcid":"https://orcid.org/0000-0002-5556-6795","observed_orcids":["https://orcid.org/0000-0002-5556-6795"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amber Balazs","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035216859","display_name":"Scott Boiko","orcid":"https://orcid.org/0009-0000-8596-6944","observed_orcids":["https://orcid.org/0009-0000-8596-6944"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott Boiko","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025265015","display_name":"Timothy P. Ikeda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Timothy P. Ikeda","raw_affiliation_strings":["Discovery Sciences, R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Sciences, R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001331637","display_name":"Anna Chiara Impastato","orcid":"https://orcid.org/0000-0001-8919-8313","observed_orcids":["https://orcid.org/0000-0001-8919-8313"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anna C. Impastato","raw_affiliation_strings":["Discovery Sciences, R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Sciences, R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069400501","display_name":"Natalie H. Jones","orcid":"https://orcid.org/0000-0002-4185-5246","observed_orcids":["https://orcid.org/0000-0002-4185-5246"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Natalie H. Jones","raw_affiliation_strings":["Discovery Sciences, R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Sciences, R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068142549","display_name":"Sameer P. Kawatkar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sameer Kawatkar","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045598309","display_name":"Paul D. Kemmitt","orcid":"https://orcid.org/0000-0002-5374-6557","observed_orcids":["https://orcid.org/0000-0002-5374-6557"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul Kemmitt","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112472356","display_name":"Scott G. Lamont","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Scott Lamont","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031235809","display_name":"Joe Sahil Patel","orcid":"https://orcid.org/0000-0002-9432-3067","observed_orcids":["https://orcid.org/0000-0002-9432-3067"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joe Patel","raw_affiliation_strings":["Discovery Sciences, R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Sciences, R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033356973","display_name":"Jon A. Read","orcid":"https://orcid.org/0000-0002-6944-3702","observed_orcids":["https://orcid.org/0000-0002-6944-3702"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Jon Read","raw_affiliation_strings":["Discovery Sciences, R&D, AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Sciences, R&D, AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102788002","display_name":"Ujjal Sarkar","orcid":"https://orcid.org/0000-0002-9214-4129","observed_orcids":["https://orcid.org/0000-0002-9214-4129"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ujjal Sarkar","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100402689","display_name":"Sha Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Li Sha","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA","Discovery Sciences, R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]},{"raw_affiliation_string":"Discovery Sciences, R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068684117","display_name":"Ronald Tomlinson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald C. Tomlinson","raw_affiliation_strings":["Discovery Sciences, R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Sciences, R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100601477","display_name":"Haiyun Wang","orcid":"https://orcid.org/0000-0002-1385-0827","observed_orcids":["https://orcid.org/0000-0002-1385-0827"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haiyun Wang","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026285477","display_name":"David M. Wilson","orcid":"https://orcid.org/0000-0002-1095-046X","observed_orcids":["https://orcid.org/0000-0002-1095-046X"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David M. Wilson","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008645663","display_name":"Troy E. Zehnder","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Troy E. Zehnder","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048879878","display_name":"Lianghe Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]},{"id":"https://openalex.org/I4405279148","display_name":"Pharmaron (China)","ror":"https://ror.org/012qm0r35","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405279148"]}],"countries":["CN","US"],"is_corresponding":false,"raw_author_name":"Lianghe Wang","raw_affiliation_strings":["Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China","Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China","institution_ids":["https://openalex.org/I4405279148"]},{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100395940","display_name":"Peng Wang","orcid":"https://orcid.org/0000-0001-8695-6721","observed_orcids":["https://orcid.org/0000-0001-8695-6721"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]},{"id":"https://openalex.org/I4405279148","display_name":"Pharmaron (China)","ror":"https://ror.org/012qm0r35","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405279148"]}],"countries":["CN","US"],"is_corresponding":false,"raw_author_name":"Peng Wang","raw_affiliation_strings":["Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China","Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China","institution_ids":["https://openalex.org/I4405279148"]},{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085108739","display_name":"Frederick W. Goldberg","orcid":"https://orcid.org/0000-0002-4874-1700","observed_orcids":["https://orcid.org/0000-0002-4874-1700"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Frederick W. Goldberg","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Cambridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Cambridge, UK","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000020580","display_name":"Wenlin Shao","orcid":"https://orcid.org/0000-0003-2417-2221","observed_orcids":["https://orcid.org/0000-0003-2417-2221","https://orcid.org/0000-0003-0894-8210"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wenlin Shao","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091683932","display_name":"Stephen E. Fawell","orcid":"https://orcid.org/0000-0002-1962-891X","observed_orcids":["https://orcid.org/0000-0002-1962-891X"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Fawell","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069306879","display_name":"Hannah Dry","orcid":"https://orcid.org/0000-0002-0706-4432","observed_orcids":["https://orcid.org/0000-0002-0706-4432"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hannah Dry","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"middle","author":{"id":null,"display_name":"James E. Dowling","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James E. Dowling","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050475544","display_name":"Scott D. Edmondson","orcid":"https://orcid.org/0000-0003-4865-2561","observed_orcids":["https://orcid.org/0000-0003-4865-2561"]},"institutions":[{"id":"https://openalex.org/I4210150756","display_name":"AstraZeneca (United States)","ror":"https://ror.org/043cec594","country_code":"US","type":"company","lineage":["https://openalex.org/I105036370","https://openalex.org/I4210150756"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott D. Edmondson","raw_affiliation_strings":["Oncology R&D, AstraZeneca, Waltham, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology R&D, AstraZeneca, Waltham, USA","institution_ids":["https://openalex.org/I4210150756"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5048914331"],"corresponding_institution_ids":["https://openalex.org/I4210150756"],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.4738,"has_fulltext":false,"cited_by_count":13,"citation_normalized_percentile":{"value":0.51359424,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"30","issue":"19","first_page":"127433","last_page":"127433"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.19509999454021454,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.19509999454021454,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.1582999974489212,"subfield":{"id":"https://openalex.org/subfields/1703","display_name":"Computational Theory and Mathematics"},"field":{"id":"https://openalex.org/fields/17","display_name":"Computer Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.08720000088214874,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/syk","display_name":"Syk","score":0.9110000133514404},{"id":"https://openalex.org/keywords/syk-inhibitors","display_name":"SYK inhibitors","score":0.9950000047683716},{"id":"https://openalex.org/keywords/kinase-inhibitors","display_name":"kinase inhibitors","score":0.5839999914169312},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.7210000157356262},{"id":"https://openalex.org/keywords/metabolic-stability","display_name":"metabolic stability","score":0.8550000190734863},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.984000027179718},{"id":"https://openalex.org/keywords/herg-inhibition","display_name":"hERG inhibition","score":0.9139999747276306},{"id":"https://openalex.org/keywords/b-cell-receptor-signaling","display_name":"B cell receptor signaling","score":0.9229999780654907},{"id":"https://openalex.org/keywords/fc-receptor-signaling","display_name":"Fc receptor signaling","score":0.9399999976158142},{"id":"https://openalex.org/keywords/chemical-probes","display_name":"chemical probes","score":0.656000018119812},{"id":"https://openalex.org/keywords/medication-optimization","display_name":"medication optimization","score":0.5090000033378601}],"concepts":[{"id":"https://openalex.org/C35174551","wikidata":"https://www.wikidata.org/wiki/Q7660502","display_name":"Syk","level":4,"score":0.9960254430770874},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.7984747886657715},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6682391166687012},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.5372728109359741},{"id":"https://openalex.org/C2779362680","wikidata":"https://www.wikidata.org/wiki/Q905000","display_name":"hERG","level":3,"score":0.5305113196372986},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4992339611053467},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4461353123188019},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.441089391708374},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.35914111137390137},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.1071588397026062},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.09621846675872803},{"id":"https://openalex.org/C83743174","wikidata":"https://www.wikidata.org/wiki/Q423778","display_name":"Potassium channel","level":2,"score":0.06713125109672546},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.bmcl.2020.127433","doi":"https://doi.org/10.1016/j.bmcl.2020.127433","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bmcl.2020.127433","pdf_url":null,"source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry Letters","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.8371999859809875,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W1444270212","https://openalex.org/W1602732476","https://openalex.org/W1608689696","https://openalex.org/W1964370181","https://openalex.org/W1994420770","https://openalex.org/W1996622616","https://openalex.org/W2006462625","https://openalex.org/W2010429563","https://openalex.org/W2014582878","https://openalex.org/W2018010296","https://openalex.org/W2018285323","https://openalex.org/W2035745525","https://openalex.org/W2039071788","https://openalex.org/W2039735251","https://openalex.org/W2067053102","https://openalex.org/W2067650781","https://openalex.org/W2077206820","https://openalex.org/W2140468880","https://openalex.org/W2279761082","https://openalex.org/W2547836952","https://openalex.org/W2603033062","https://openalex.org/W2805876975","https://openalex.org/W2900277945","https://openalex.org/W2966519116"],"related_works":["https://openalex.org/W4378979571","https://openalex.org/W2508034878","https://openalex.org/W2325364816","https://openalex.org/W2068259663","https://openalex.org/W3082206450","https://openalex.org/W2984352693","https://openalex.org/W4393930716","https://openalex.org/W2530153295","https://openalex.org/W2289505052","https://openalex.org/W2020081835"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-05-11T00:00:00"}